Campus de Goiabeiras, Vitória - ES

Name: NATALIA ASSIS GUEDES

Publication date: 11/11/2025

Examining board:

Namesort descending Role
ADILSON VIDAL COSTA Examinador Interno
ALVARO CUNHA NETO Examinador Interno
LUCAS DE SOUZA SOARES Examinador Externo
RÓBSON RICARDO TEIXEIRA Examinador Externo
VAGNER TEBALDI DE QUEIROZ Coorientador

Summary: In this work, triazole derivatives of nucleosides were synthesized via the CuAAC reaction (copper(I)-catalyzed alkyne-azide cycloaddition) under microwave irradiation. The structures of compounds 3a–3j were confirmed by Fourier-transform infrared spectroscopy (FTIR), 1H and 13C nuclear magnetic resonance (NMR), showing characteristic signals of AZT and the triazole, with H-8 (7.76–7.83 ppm), CH3-9 (1.77– 2.06 ppm), and H-triazole (8.03–9.05 ppm) appearing as singlets, and by mass spectrometry. The compounds were obtained in yields ranging from 58.7 to 97.7%. Luminescence assays showed that compounds 3a and 3j stood out as inhibitors of SARS-CoV-2 Mpro and BCR-ABL kinase. In Mpro, 3j exhibited an IC50 of 25.15 µM and 3a of 89.18 µM, while 3e showed 168.10 µM; the other compounds did not significantly inhibit the enzyme. In BCR-ABL, 3j and 3a showed IC50 values of 0.44 µM and 0.78 µM, respectively, while 3b exhibited 150 µM and the remaining compounds were inactive. These results indicate that 3a and 3j have a promising profile as multitarget inhibitors. Molecular docking studies supported the experimental data. Compound 3a formed hydrogen bonds with key residues of Mpro, as well as hydrophobic and aromatic interactions that contribute to complex stability. In BCRABL, 3a and 3j also established hydrogen bonds and aromatic interactions. Overall, the studied triazoles demonstrated a good ability to interact with the active sites of both enzymes, suggesting potential as multi-target inhibitors. As this is an initial study, cellular assays and in vivo models are needed to confirm their biological efficacy. This work is expected to contribute to the development of new therapeutic inhibitors and to inspire future research in the field.

Access to document

Transparência Pública
Acesso à informação

© 2013 Universidade Federal do Espírito Santo. Todos os direitos reservados.
Av. Fernando Ferrari, 514 - Goiabeiras, Vitória - ES | CEP 29075-910